利伐沙班与阿司匹林对隐源性卒中复发风险的比较:基于房颤预测因素的NAVIGATE ESUS二次分析
NAVIGATE ESUS随机试验的二次分析纳入7112例隐源性卒中患者,按房颤预测因素分层。结果显示,HAVOC评分、左心房直径和房性早搏频率均能预测随访中新发房颤;
要点
- HAVOC评分、左心房直径和房性早搏频率可预测隐源性卒中后的临床房颤。
- 左心房直径>4.6 cm的患者使用利伐沙班可能降低卒中复发风险。
- 该亚组结果需独立验证后才能影响临床实践。
核心结论
- 在隐源性卒中患者中,利伐沙班对卒中复发的减少作用与HAVOC评分及房性早搏频率无关,但在左心房直径>4.6 cm的亚组中观察到利伐沙班优于阿司匹林。
研究设计与样本
- NAVIGATE ESUS随机临床试验的二次分析,纳入2014年12月至2017年9月入组的7112例隐源性卒中患者,按房颤预测因素分层评估治疗交互作用。
主要发现
- 随访期间房颤检出率随HAVOC评分三分位升高:2.3%(0-2分)、3.0%(3分)、5.8%(>3分)。
- 房颤年发病率随左心房直径三分位升高:2.0%、3.6%、5.2%;随房性早搏频率三分位升高:1.3%、2.9%、7.0%。
临床怎么用
- 对隐源性卒中患者可评估左心房直径,左心房直径>4.6 cm者使用利伐沙班可能获益,但需进一步验证。
局限性
- 左心房直径>4.6 cm亚组样本量较小,结果需独立确认后方可用于临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The NAVIGATE ESUS randomized clinical trial found that 15 mg of rivaroxaban per day does not reduce stroke compared with aspirin in patients with embolic stroke of undetermined source (ESUS); however, it substantially reduces stroke risk in patients with atrial fibrillation (AF). OBJECTIVE: To analyze whether rivaroxaban is associated with a reduction of recurrent stroke among patients with ESUS who have an increased risk of AF. DESIGN, SETTING, AND PARTICIPANTS: Participants were stratified by predictors of AF, including left atrial diameter, frequency of premature atrial contractions, and HAVOC score, a validated scheme using clinical features. Treatment interactions with these predictors were assessed. Participants were enrolled between December 2014 and September 2017, and analysis began March 2018. INTERVENTION: Rivaroxaban treatment vs aspirin. MAIN OUTCOMES AND MEASURES: Risk of ischemic stroke. RESULTS: Among 7112 patients with a mean (SD) age of 67 (9.8) years, the mean (SD) HAVOC score was 2.6 (1.8), the mean (SD) left atrial diameter was 3.8 (1.4) cm (n = 4022), and the median (interquartile range) daily frequency of premature atrial contractions was 48 (13-222). Detection of AF during follow-up increased for each tertile of HAVOC score: 2.3% (score, 0-2), 3.0% (score, 3), and 5.8% (score, >3); however, neither tertiles of the HAVOC score nor premature atrial contractions frequency impacted the association of rivaroxaban with recurrent ischemic stroke (P for interaction = .67 and .96, respectively). Atrial fibrillation annual incidence increased for each tertile of left atrial diameter (2.0%, 3.6%, and 5.2%) and for each tertile of premature atrial contractions frequency (1.3%, 2.9%, and 7.0%). Among the predefined subgroup of patients with a left atrial diameter of more than 4.6 cm (9% of overall population), the risk of ischemic stroke was lower among the rivaroxaban group (1.7% per year) compared with the aspirin group (6.5% per year) (hazard ratio, 0.26; 95% CI, 0.07-0.94; P for interaction = .02). CONCLUSIONS AND RELEVANCE: The HAVOC score, left atrial diameter, and premature atrial contraction frequency predicted subsequent clinical AF. Rivaroxaban was associated with a reduced risk of recurrent stroke among patients with ESUS and moderate or severe left atrial enlargement; however, this needs to be independently confirmed before influencing clinical practice.
引用
- Healey JS, Gladstone DJ, Swaminathan B, et al. Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial. JAMA Neurol. 2019. PMID: 30958508. doi:10.1001/jamaneurol.2019.0617
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。